A federal appeals court has revived private lawsuits that seek to hold Tylenol makers and retailers liable for alleged links between acetaminophen use during pregnancy and autism spectrum disorder in children. The ruling reverses earlier dismissals and clears plaintiffs to pursue their claims, potentially drawing in Johnson & Johnson — which still licenses and profits from the Tylenol brand — as well as retailers like CVS, Walgreens, and store-brand manufacturers that sold acetaminophen products.

For JNJ specifically, the litigation overhang arrives at a complex moment. The company posted $94.2B in revenue for FY2025, up 6% year-over-year, with a robust 67.9% gross margin and $11.03 in diluted EPS — a fundamentally strong business. However, JNJ has an extensive history of large-scale mass tort exposure (talc, opioids, mesh) and investors are well-trained to treat appellate-level litigation reversals seriously, as they reset the liability timeline.

The second-order setup is a potential re-rating of JNJ's litigation discount. If the case class grows and plaintiffs successfully establish a causation standard in court, the liability pool could be substantial given the widespread use of Tylenol during pregnancy over decades. The key unknowns are how courts handle the scientific causation question — which remains contested — and whether JNJ attempts another Texas two-step bankruptcy maneuver to ring-fence liability, as it tried with talc.

Near-term, the ruling is unlikely to produce immediate financial impact, but it introduces headline risk and may suppress the stock's multiple. Watchers should monitor the appeals court's specific remand instructions, any early settlement signals, and whether plaintiffs' attorneys move to consolidate into a large MDL (multidistrict litigation). The bull case hinges on the science being ruled insufficient for causation; the bear case is a repeat of the talc trajectory.